Citadel Advisors’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q3 | – | Sell |
-26,200
| Closed | -$872K | – | 11103 |
|
|
2020
Q2 | $872K | Buy |
26,200
+7,000
| +36% | +$223K | ﹤0.01% | 6077 |
|
|
2020
Q1 | $522K | Buy |
19,200
+6,600
| +52% | +$184K | ﹤0.01% | 6393 |
|
|
2019
Q4 | $249K | Buy |
+12,600
| New | +$201K | ﹤0.01% | 7867 |
|
|
2019
Q2 | – | Sell |
-23,400
| Closed | -$340K | – | 10185 |
|
|
2019
Q1 | $340K | Sell |
23,400
-4,300
| -16% | -$54.9K | ﹤0.01% | 7431 |
|
|
2018
Q4 | $306K | Sell |
27,700
-12,100
| -30% | -$168K | ﹤0.01% | 7231 |
|
|
2018
Q3 | $1.05M | Buy |
39,800
+24,400
| +158% | +$660K | ﹤0.01% | 5459 |
|
|
2018
Q2 | $315K | Sell |
15,400
-5,700
| -27% | -$122K | ﹤0.01% | 7130 |
|
|
2018
Q1 | $383K | Buy |
21,100
+8,400
| +66% | +$140K | ﹤0.01% | 6336 |
|
|
2017
Q4 | $177K | Buy |
+12,700
| New | +$172K | ﹤0.01% | 7192 |
|
|
2017
Q3 | – | Sell |
-13,900
| Closed | -$235K | – | 8295 |
|
|
2017
Q2 | $235K | Buy |
13,900
+1,200
| +9% | +$18.3K | ﹤0.01% | 6314 |
|
|
2017
Q1 | $170K | Buy |
12,700
+1,800
| +17% | +$28.2K | ﹤0.01% | 6632 |
|
|
2016
Q4 | $164K | Sell |
10,900
-13,900
| -56% | -$184K | ﹤0.01% | 6450 |
|
|
2016
Q3 | $290K | Buy |
24,800
+13,500
| +119% | +$159K | ﹤0.01% | 5724 |
|
|
2016
Q2 | $122K | Sell |
11,300
-1,200
| -10% | -$12.4K | ﹤0.01% | 6109 |
|
|
2016
Q1 | $116K | Hold |
12,500
| – | – | ﹤0.01% | 5962 |
|
|
2015
Q4 | $186K | Sell |
12,500
-25,500
| -67% | -$427K | ﹤0.01% | 5902 |
|
|
2015
Q3 | $624K | Buy |
38,000
+14,900
| +65% | +$305K | ﹤0.01% | 4477 |
|
|
2015
Q2 | $527K | Buy |
23,100
+8,400
| +57% | +$167K | ﹤0.01% | 4888 |
|
|
2015
Q1 | $223K | Sell |
14,700
-13,400
| -48% | -$174K | ﹤0.01% | 6058 |
|
|
2014
Q4 | $338K | Buy |
28,100
+14,200
| +102% | +$162K | ﹤0.01% | 5257 |
|
|
2014
Q3 | $158K | Sell |
13,900
-3,200
| -19% | -$36.5K | ﹤0.01% | 5980 |
|
|
2014
Q2 | $207K | Sell |
17,100
-11,300
| -40% | -$133K | ﹤0.01% | 5532 |
|
|
2014
Q1 | $331K | Buy |
28,400
+11,600
| +69% | +$196K | ﹤0.01% | 4904 |
|
|
2013
Q4 | $297K | Sell |
16,800
-4,900
| -23% | -$82.3K | ﹤0.01% | 4613 |
|
|
2013
Q3 | $312K | Sell |
21,700
-1,000
| -4% | -$15.3K | ﹤0.01% | 4300 |
|
|
2013
Q2 | $342K | Buy |
+22,700
| New | +$300K | ﹤0.01% | 4183 |
|
Citadel Advisors's MNTA Position: Q4 2020 in Review
Citadel Advisors sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q4 2020, closing a stake of 836,737 shares — an estimated $43.9M sold.
Citadel Advisors first reported a position in MNTA in Q2 2013 and held it in 23 quarters. The position peaked at $58.7M in Q2 2020. 0 funds tracked by Wall St. Rank hold MNTA as of Q4 2020.
- Citadel Advisors reported no remaining Momenta Pharmaceuticals, Inc. position as of Q4 2020 after selling out during the quarter.
- Citadel Advisors sold 836,737 Momenta Pharmaceuticals, Inc. shares in Q4 2020, an estimated $43.9M.
- Citadel Advisors first reported a position in Momenta Pharmaceuticals, Inc. in Q2 2013 and held it in 23 quarters.
- Citadel Advisors's Momenta Pharmaceuticals, Inc. position peaked at $58.7M in Q2 2020.
- 0 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q4 2020.
Based on Citadel Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.